Importer of Controlled Substances Application: Sigma Aldrich Co., LLC, 22178-22179 [2020-08354]
Download as PDF
<![CDATA[
22178
Federal Register / Vol. 85, No. 77 / Tuesday, April 21, 2020 / Notices
In light of
the ongoing Coronavirus (COVID–19)
outbreak, the Commission has
determined to extend postponement of
all section 337 in-person hearings until
June 10, 2020. Commission
Administrative Law Judges (‘‘ALJ’’) are
directed to notify all affected parties and
to schedule new dates for the hearings
as appropriate. ALJs may otherwise
conduct their investigations in
accordance with their established
procedures.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
SUPPLEMENTARY INFORMATION:
By order of the Commission.
Issued: April 15, 2020.
Lisa Barton,
Secretary to the Commission.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 3, 2018,
Cedarburg Pharmaceuticals, 870 Badger
Circle, Grafton, Wisconsin 53024–0000
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Tetrahydrocannabinols ..
Methylphenidate ............
Nabilone ........................
4-Anilino-N-phenethyl-4piperidine (ANPP).
Fentanyl .........................
Schedule
7370
1724
7379
8333
I
II
II
II
9801
II
[FR Doc. 2020–08388 Filed 4–20–20; 8:45 am]
The company plans to manufacture
bulk active pharmaceutical ingredients
(API) for distribution to its customers. In
reference to drug code 7370
(Tetrahydrocannabinols) the company
plans to bulk manufacture as synthetic.
No other activity for this drug code is
authorized for this registration.
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–596]
Bulk Manufacturer of Controlled
Substances Application: Cedarburg
Pharmaceuticals
ACTION:
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–08352 Filed 4–20–20; 8:45 am]
Notice of application.
BILLING CODE 4410–09–P
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 22, 2020.
DATES:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–606]
Importer of Controlled Substances
Application: Sigma Aldrich Co., LLC
ACTION:
Notice of application.
Registered bulk manufacturer of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 21, 2020. Such persons
may also file a written request for a
hearing on the application on or before
May 21, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on January 27, 2020,
Sigma Aldrich Co., LLC, 3500 DeKalb
Street, Saint Louis, Missouri 63118
applied to be registered as an importer
of the following basic class(es) of
controlled substances:
DATES:
lotter on DSKBCFDHB2PROD with NOTICES
Controlled substance
Drug code
Cathinone ........................................................................................................................................................................
Methcathinone .................................................................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ....................................................................................................................
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine .............................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine ..........................................................................................................................
2,5-Dimethoxyamphetamine ............................................................................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine .......................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
N-Benzylpiperazine ..........................................................................................................................................................
Heroin ..............................................................................................................................................................................
Normorphine ....................................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Nabilone ...........................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Ethylmorphine ..................................................................................................................................................................
VerDate Sep<11>2014
21:19 Apr 20, 2020
Jkt 250001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\21APN1.SGM
21APN1
1235
1237
1248
2010
7370
7391
7392
7396
7400
7404
7405
7411
7435
7493
9200
9313
2125
2315
7379
7471
9180
9190
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
22179
Federal Register / Vol. 85, No. 77 / Tuesday, April 21, 2020 / Notices
Controlled substance
Drug code
Levorphanol .....................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Opium, powdered ............................................................................................................................................................
Levo-alphacetylmethadol .................................................................................................................................................
The company plans to import the
listed controlled substances for sale to
research facilities for drug testing and
analysis. In reference to drug code 7370
(Tetrahydrocannabinols) the company
plans to import synthetic
tetrahydrocannabinols. No other
activities for these drug codes are
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–08354 Filed 4–20–20; 8:45 am]
BILLING CODE 4410–09–P
NATIONAL ARCHIVES AND RECORDS
ADMINISTRATION
[NARA–2020–036]
Freedom of Information Act (FOIA)
Advisory Committee; Meeting
Office of Government
Information Services (OGIS), National
Archives and Records Administration
(NARA).
ACTION: Notice of Federal Advisory
Committee meeting.
AGENCY:
We are announcing an
upcoming Freedom of Information Act
(FOIA) Advisory Committee meeting in
accordance with the Federal Advisory
Committee Act and the second United
States Open Government National
Action Plan.
DATES: The meeting will be on May 1,
2020, from 10:00 a.m. to 1:30 p.m. EST.
You must register by midnight EST
April 28, 2020, to attend the meeting.
Location: This meeting will be held
virtually. Instructions on how to access
will be sent to those who register
according to instructions below.
FOR FURTHER INFORMATION CONTACT:
Kirsten Mitchell, Designated Federal
Officer for this committee, by email at
foia-advisory-committee@nara.gov or by
telephone at 202.741.5770.
SUPPLEMENTARY INFORMATION:
Agenda and meeting materials: This
is the eighth meeting of the third
committee term. The Committee will
discuss the report of the committee and
consider additional recommendations
from the Committee’s three
subcommittees, focusing on FOIA
vision, time/volume, and records
lotter on DSKBCFDHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
21:19 Apr 20, 2020
Jkt 250001
management. We will post meeting
materials online at https://
www.archives.gov/ogis/foia-advisorycommittee/2018-2020-term/meetings.
Procedures: This virtual meeting is
open to the public. You must register
through Eventbrite in advance if you
wish to attend, and you must provide an
email address so that we can provide
information to you on accessing the
meeting online. Because of scheduling
complications related to the COVID–19
situation and notice processing time, we
have not been able to provide the full
15-day notice before this advisory
committee meeting. We apologize for
the inconvenience. To request
additional accommodations (e.g., a
transcript), email foia-advisorycommittee@nara.gov or call
202.741.5775. Members of the media
who wish to register, those who are
unable to register online, and those who
require special accommodations, should
contact Kirsten Mitchell (contact
information listed above).
Maureen MacDonald,
Designated Committee Management Officer.
[FR Doc. 2020–08357 Filed 4–20–20; 8:45 am]
BILLING CODE 7515–01–P
NATIONAL ARCHIVES AND RECORDS
ADMINISTRATION
[NARA–20–0010; NARA–2020–035]
Records Schedules; Availability and
Request for Comments
National Archives and Records
Administration (NARA).
ACTION: Notice of availability of
proposed records schedules; request for
comments
AGENCY:
The National Archives and
Records Administration (NARA)
publishes notice of certain Federal
agency requests for records disposition
authority (records schedules). We
publish notice in the Federal Register
and on regulations.gov for records
schedules in which agencies propose to
dispose of records they no longer need
to conduct agency business. We invite
public comments on such records
schedules.
DATES: We must receive comments by
June 5, 2020.
SUMMARY:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
9220
9230
9333
9639
9648
Schedule
II
II
II
II
II
You may submit comments
by either of the following methods. You
must cite the control number, which
appears on the records schedule in
parentheses after the name of the agency
that submitted the schedule.
• Federal eRulemaking Portal: https://
www.regulations.gov.
• Mail: Records Appraisal and
Agency Assistance (ACR); National
Archives and Records Administration;
8601 Adelphi Road; College Park, MD
20740–6001.
FOR FURTHER INFORMATION CONTACT:
Kimberly Keravuori, Regulatory and
External Policy Program Manager, by
email at regulation_comments@
nara.gov. For information about records
schedules, contact Records Management
Operations by email at
request.schedule@nara.gov, by mail at
the address above, or by phone at 301–
837–1799.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Public Comment Procedures
We are publishing notice of records
schedules in which agencies propose to
dispose of records they no longer need
to conduct agency business. We invite
public comments on these records
schedules, as required by 44 U.S.C.
3303a(a), and list the schedules at the
end of this notice by agency and
subdivision requesting disposition
authority.
In addition, this notice lists the
organizational unit(s) accumulating the
records or states that the schedule has
agency-wide applicability. It also
provides the control number assigned to
each schedule, which you will need if
you submit comments on that schedule.
We have uploaded the records
schedules and accompanying appraisal
memoranda to the regulations.gov
docket for this notice as ‘‘other’’
documents. Each records schedule
contains a full description of the records
at the file unit level as well as their
proposed disposition. The appraisal
memorandum for the schedule includes
information about the records.
We will post comments, including
any personal information and
attachments, to the public docket
unchanged. Because comments are
public, you are responsible for ensuring
that you do not include any confidential
or other information that you or a third
E:\FR\FM\21APN1.SGM
21APN1
]]>Agencies
[Federal Register Volume 85, Number 77 (Tuesday, April 21, 2020)]
[Notices]
[Pages 22178-22179]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08354]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-606]
Importer of Controlled Substances Application: Sigma Aldrich Co.,
LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturer of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before May 21, 2020.
Such persons may also file a written request for a hearing on the
application on or before May 21, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on January 27, 2020, Sigma Aldrich Co., LLC, 3500 DeKalb
Street, Saint Louis, Missouri 63118 applied to be registered as an
importer of the following basic class(es) of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Cathinone.......................... 1235 I
Methcathinone...................... 1237 I
Mephedrone (4-Methyl-N- 1248 I
methylcathinone).
Gamma Hydroxybutyric Acid.......... 2010 I
Tetrahydrocannabinols.............. 7370 I
4-Bromo-2,5-dimethoxyamphetamine... 7391 I
4-Bromo-2,5-dimethoxyphenethylamine 7392 I
2,5-Dimethoxyamphetamine........... 7396 I
3,4-Methylenedioxyamphetamine...... 7400 I
3,4-Methylenedioxy-N- 7404 I
ethylamphetamine.
3,4-Methylenedioxymethamphetamine.. 7405 I
4-Methoxyamphetamine............... 7411 I
Dimethyltryptamine................. 7435 I
N-Benzylpiperazine................. 7493 I
Heroin............................. 9200 I
Normorphine........................ 9313 I
Amobarbital........................ 2125 II
Secobarbital....................... 2315 II
Nabilone........................... 7379 II
Phencyclidine...................... 7471 II
Ecgonine........................... 9180 II
Ethylmorphine...................... 9190 II
[[Page 22179]]
Levorphanol........................ 9220 II
Meperidine......................... 9230 II
Thebaine........................... 9333 II
Opium, powdered.................... 9639 II
Levo-alphacetylmethadol............ 9648 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
sale to research facilities for drug testing and analysis. In reference
to drug code 7370 (Tetrahydrocannabinols) the company plans to import
synthetic tetrahydrocannabinols. No other activities for these drug
codes are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-08354 Filed 4-20-20; 8:45 am]
BILLING CODE 4410-09-P
